Pfizer (PFE, Financial) has finalized the sale of its entire holding in Haleon (HLN, Financial), generating approximately £2.5 billion ($3.24 billion), Reuters reported Wednesday, citing a bookrunner involved in the transaction.
The pharmaceutical company, which co-founded Haleon alongside British drugmaker GSK (GSK, Financial) in 2019, offloaded around 662 million shares, equal to a 7.3% stake. The shares were priced at 385 pence each.
As part of the deal, Haleon repurchased 44 million shares directly from Pfizer, while institutional investors acquired the remaining 618 million.
Bloomberg News previously disclosed on Tuesday that Pfizer planned to fully exit its stake in Haleon, a process that had been underway since the company's separation from GSK in 2022.
With GSK having completed its divestment in May, BlackRock Investment Management (UK) Ltd., a subsidiary of BlackRock (BLK, Financial), is set to become Haleon's largest shareholder, holding over 5% of its shares, according to Reuters, citing LSEG data.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。